^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Hairy Cell Leukemia |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of the clinical activity and safety of vemurafenib (PLX-4032) in previously treated patients with hairy cell leukemia carrying the BRAF-V600E mutation Studio sull’attivita' clinica e la sicurezza di vemurafenib (PLX-4032), in pazienti con Leucemia a Cellule Capellute positivi alla mutazione BRAF-V600E e precedentemente trattati.
Excerpt:
...Proven diagnosis of HCL according to the morphological and immunophenotypic criteria (co-expression of CD11c/CD25/CD103 and/or positivivity for annexin-A1) of the World Health Organization (WHO-2008) classification of lymphoid neoplasms, accompanied by the presence of the BRAF-V600E mutation 3. ...
Trial ID:
Source:
Title:
VEMURAFENIB AS TREATMENT OPTION FOR HAIRY CELL LEUKEMIA WITH DEEP NEUTROPENIA AND INFECTIOUS COMPLICATIONS
Published date:
05/14/2020
Excerpt:
The diagnosis of HCL was established in accordance with generally accepted clinical and laboratory criteria...PCR analysis of the V600E mutation of the BRAF gene...All 18 patients with prolonged use of vemurafenib ≥ 3 months reached a response - an increase in neutrophils >1,0х109 / l (1,1 - 2,7 х109 / l ), normalization of hemoglobin, increasing of platelet count >100x109 / l, reduction size of the spleen . Then, after 3 months of treatment with vemurafenib, a standard course of cladribine was given, 17 patients achieved complete remission and one patient had good partial remission.
Source:
Title:
Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl
Excerpt:
A total of 36 pts were enrolled to the study…The ORR was 86% (31/36 pts), including 33% CR (12/36) and 53% PR (19/36). With a median follow-up of 24 months (range, 1-64 months), 18 pts (50%) experienced relapse….With a longer follow-up duration of up to 64 months, we confirm the high response rates with vemurafenib monotherapy in pts with R/R HCL and a favorable safety profile.
DOI:
https://doi.org/10.1182/blood-2018-99-119949
Source:
Title:
Rapid response of biallelic BRAF V 600E mutated hairy cell leukaemia to low dose vemurafenib
Excerpt:
...the first use of 58 d of continuous low dose vemurafenib to successfully induce a partial remission with striking clinical benefit for our patient who had a biallelic V600E mutation….
DOI:
https://doi.org/10.1111/bjh.12201
Source:
Title:
Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation
Excerpt:
...used vemurafenib to treat a 72-year old patient who presented with a relapse of HCL and the BRAF V600E mutation….inhibition of mutated BRAF by vemurafenib may represent an important therapeutic advancement for the treatment of HCL.
DOI:
https://dx.doi.org/10.3324%2Fhaematol.2012.082404
Source:
Title:
Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib
Excerpt:
...we present a successful re-treatment schema of a relapsed V600E mutated HCL with low-dose vemurafenib….We also showed that vemurafenib re-treatment of HCL patient experiencing a relapse after a first round of vemurafenib is highly efficient to induce death of leukemic cells and a quick normalization of patient's blood formulation.
DOI:
10.18632/oncoscience.111
Trial ID:
